Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Long Term Study With B2036-PEG

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00143416
Recruitment Status : Completed
First Posted : September 2, 2005
Last Update Posted : July 29, 2008
Information provided by:

Brief Summary:
Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.

Condition or disease Intervention/treatment Phase
Acromegaly Drug: Pegvisomant Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 16 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Long-Term Study of B2036-PEG in Acromegaly - Long Term Study With B2036-PEG -
Study Start Date : April 2004
Actual Study Completion Date : July 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Pegvisomant

Primary Outcome Measures :
  1. To evaluate the safety and efficacy of long-term B2036-PEG therapy in patients with acromegaly

Secondary Outcome Measures :
  1. PK/PD evaluation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with acromegaly who have received at least one dose of B2036-PEG in the preceding study (A6291009).

Exclusion Criteria:

  • Switching to other therapeutic methods for acromegaly

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00143416

Layout table for location information
Pfizer Investigational Site
Kobe City, Hyogo Pref, Japan, 650-0017
Pfizer Investigational Site
Kozukue-cho, Kouhoku-ku, Yokohama-shi, Kanagawa, Japan, 222-0036
Pfizer Investigational Site
Hamamatsu-shi, Shizuoka-ken, Japan, 431-3124
Pfizer Investigational Site
Bonkyo-ku, Tokyo, Japan, 113-0022
Pfizer Investigational Site
Shinjuku-ku, Tokyo, Japan, 162-8666
Pfizer Investigational Site
Gakuhara, Kishiwada, Osaka, Japan, 596-8501
Pfizer Investigational Site
Kyoto, Japan, 612-8555
Pfizer Investigational Site
Sannomaru-cho, Naka-ku, Nagoya-shi, Japan, 460-0001
Sponsors and Collaborators
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer
Additional Information:
Layout table for additonal information Identifier: NCT00143416    
Other Study ID Numbers: A6291011
First Posted: September 2, 2005    Key Record Dates
Last Update Posted: July 29, 2008
Last Verified: July 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Bone Diseases, Endocrine
Bone Diseases
Musculoskeletal Diseases
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases